Kepler Uniklinikum Joins SOPHiA DDM™ Platform
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a...
Category : Health Diagnostics
Agilent Announces Cutting-Edge Advances in Technology at ASMS 2024
Agilent Technologies Inc., (NYSE: A) is introducing two new products at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics. The Agilent 7010D Triple Quadrupole...
Tempus Announces Expansion of Collaboration with AstraZeneca
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology...
AI-powered lung cancer care continuum unveiled at ASCO 2024
World’s most widely used medical imaging AI innovator debuts vision of early lung cancer detection and care To further the fight against global lung cancer, Qure.ai,...
CancerLinQ Enables Learning Network and Precision Oncology Solutions
CancerLinQ®, the precision oncology care and research platform, originally founded by the American Society of Clinical Oncology (ASCO®) and now an initiative of ConcertAI, deploys...
SKT Launches AI-powered Veterinary Diagnostic Assistance Service X Caliber
In collaboration with ATX Medical Solutions, SKT launches X Caliber in Australia, which has one of the highest rates of pet ownership in the world SKT...
iHealthScreen’s Risk Prediction via Retinal Images & Health Data.
The stroke and heart attack prediction results will be presented at the 47th Congress of the European Society of Cardiology (ESC), London, UK, from 30th...
MaximBio & Thomas Scientific Ink Marketing Agreement for ClearDetectTM
Today, Maxim Biomedical (MaximBio), a leading diagnostic healthcare company and manufacturer of trusted diagnostic solutions announced a comprehensive Marketing and Distribution Agreement with Thomas Scientific...
MYND Diagnostics begins Clinical Research on Alzheimer’s Disease
The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics MYND LIFE SCIENCES INC. (“MYND” or...
Medivolve Announces Q3 2021 Results
Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021. Gross profit was $10.5 million in the...